Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients-11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P = 0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
INTRODUCTION
Follicular lymphoma (FL) is the third most common B-cell lymphoma in Japan 1 and the second most common lymphoma diagnosed in the United States and Western Europe. 2, 3 The use of rituximab in addition to conventional chemotherapy has been demonstrated to improve the overall survival (OS) in patients with untreated advanced-stage FL by three phase III randomized trials. [4] [5] [6] However, most of the patients relapsed after conventional chemotherapy and so rituximab-containing chemotherapy regimens have not been considered curative. High-dose therapy (HDT) followed by autologous stem cell transplantation (auto-SCT) in FL was reported by Schouten et al. 7 for the first time. Although a prospective randomized trial revealed that HDT with auto-SCT should not be recommended as consolidation therapy in first CR (CR1), 8 longer OS could be obtained when HDT and auto-SCT were undertaken in second PR (PR2) or CR2 than in subsequent progression. 9, 10 Allogeneic stem cell transplantation (allo-SCT) is another curative option for patients with relapsed FL. It can be considered for those who have relapsed after HDT followed by auto-SCT, those in whom peripheral stem cells could not be collected or those heavily pretreated with immunochemotherapy (that is, those having received ⩾ 3 prior regimens). Although allo-SCT offers the advantage of reducing the risk of relapse/progression due to the graft-versus-lymphoma (GVL) effect, the risk of nonrelapse mortality (NRM) is of major concern. Reducedintensity conditioning (RIC) and nonmyeloablative conditioning have been demonstrated to reduce the toxicity of allo-SCT, and prospective trials have demonstrated promising results of these conditioning regimens in relapsed FL or indolent B-cell lymphoma. [11] [12] [13] [14] Khouri et al. 11 showed excellent results of nonmyeloablative conditioning with fludarabine (Flu), cyclophosphamide (CY) and rituximab for relapsed chemosensitive FL. They described that the estimated OS and progression-free survival (PFS) were 85 and 83%, and that none of the patients died of recurrent lymphoma. The GELTAMO group indicated that RIC allo-SCT with Flu and melphalan (Mel)-based regimens could markedly reduce the rate of relapse/progression, although 18% of patients had progressive/refractory disease.
14 They showed that relapse/ progression occurred in only 3 of the 37 patients after allo-SCT, whereas they indicated that progressive/refractory disease at the time of transplant increased the risk of NRM. These prospective studies of RIC revealed that chemosensitivity is the most reliable predictor of outcome. [11] [12] [13] [14] However, the trials included patients with mostly chemosensitive disease, so limited data are available for patients with progressive/refractory disease at the time of transplantation.
We report here a retrospective analysis of RIC allo-SCT for 46 patients with FL at the Kanto Study Group for Cell Therapy, including 29 patients (63%) with progressive/refractory disease. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL.
PATIENTS AND METHODS Patients
The Kanto Study Group for Cell Therapy is a voluntary group of 25 transplant centers in the Kanto region of Japan. The study population included patients with FL who underwent RIC allo-SCT between June 2001 and June 2009. There were 46 patients identified as being eligible for the study, and 19 of them have been reported previously. 15 
Study definitions
Conditioning regimens included ⩽ 8 Gy in fractionated doses of TBI, busulfan dose o9 mg/kg (or intravenous equivalent) and Mel dose ⩽ 140 mg/m 2 defined as RIC regimens. 16 CR, PR and relapsed/progressive disease were determined by standard disease-specific criteria, as defined by the National Cancer Institute. 17, 18 OS was defined as the time from the day of transplantation to death from any cause. NRM included all causes of death other than disease progression/relapse after transplantation.
Transplantation procedure
Most of the patients (96%) received Flu-Mel-based conditioning regimens or Flu-CY-based regimens.
GvHD prophylaxis was based on tacrolimus or cyclosporine plus shortterm methotrexate in 43 of 46 patients. Two patients received cyclosporine in combination with either mycophenolate mofetil or prednisolone, and one patient received cyclosporine alone.
Infection prophylaxis was performed for all patients according to the institutional guidelines. CMV reactivation was managed in a manner dependent on the institutional policy.
Statistical analysis
The probabilities of OS and PFS were calculated using the Kaplan-Meier method. Survival curves were compared using the log-rank test. NRM was calculated by treating relapse/progression as a competing risk. Relapse/progression and NRM curves were compared using the Gray test. Death without GvHD and death with disease were treated as competing risks for acute and chronic GvHD. P-values o 0.05 were considered statistically significant. Proportional-hazard modeling was used for univariate analyses. Multivariate analysis was performed by a stepwise method using threshold values for removal from the model at P = 0.10. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 19 which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0, Vienna, Austria).
RESULTS

Patients' characteristics
We analyzed 46 patients with FL who underwent allo-SCT. The patients' characteristics are summarized in Table 1 . Median age was 48 (34-66) years. The time from diagnosis to allo-SCT ranged from 0.2 to 19.4 years (median, 2.9 years). Patients had received a median of three (range, 1-9) chemotherapy regimens before allo-SCT and three patients (7%) had received auto-SCT. Eleven patients (24%) had been transplanted in CR, six patients (13%) in PR and 29 patients (63%) had progressive/refractory disease. Conditioning regimens included Flu-Mel-based regimens (74%), Flu-CY-based regimens (22%) or other regimens (4%).
Survival, relapse/progression and NRM Median follow-up among surviving patients from allo-SCT to the last known vital status was 3.7 (range, 0.3-8.1) years. Two patients died before achieving neutrophil engraftment. The remaining 44 patients had sustained neutrophil recovery exceeding 0.5 × 10 3 /μL for three consecutive days, with a median time of 16 (range, 6-40) days. Among these 44 patients, 39 (88.6%) obtained CR, including patients continuing their CR. Six patients developed relapse/ progressive disease after allo-SCT. The estimated 5-year OS and PFS were 71.6% (95% confidence interval (CI), 51.5-84.5%) and 62.5% (95% CI, 43.0-77.0%), respectively. According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P = 0.29; Figure 1a ). The PFS at 5-year for those with CR or PR was 74.9% (95% CI, 37.1-91.9%), compared with 55.1% (95% CI, 31.6-73.5%) for those with progressive/refractory disease (P = 0.18; Figure 1b ). There were no significant differences in OS and PFS between the patients with chemosensitive disease and progressive/ refractory disease. In univariate analysis, other variables such as age, sex, number of chemotherapies before transplant, IgG level at transplant and stem cell source did not show a significant impact on survival (Table 2) . Meanwhile, multivariate analysis showed that male patients had an unfavorable OS compared with females (hazard ratio (HR), 9.00; 95% CI, 1.11-73.2; P = 0.04; Table 3 ).
Relapse/progression occurred in six patients at a median time of 8.2 months (range, 1.0-18.3 months). The cumulative incidence of relapse/progression at 5 years was 14.8% (95% CI, 5.9-27.6%). Abbreviation: FL = follicular lymphoma.
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According to the disease status at transplantation, the 5-year relapse/progression rates were 6.7% (95% CI, 0.4-27.1%) in the patients with CR or PR and 19.3% (95% CI, 6.8-36.6%) in those with progressive/refractory disease (P = 0.28; Figure 2 ). In univariate analysis, no variables such as age, sex, number of chemotherapies and low IgG level of o 700 mg/dL and stem cell source influenced relapse/progression (Table 2) . Conditioning regimens had no significant impact on OS and relapse ( Table 2 ). The 5-year relapse/progression rate in the patients with progressive/refractory disease seemed to be lower in the Flu-Mel-based regimens than in the Flu-CY-based ones (13.8%; 95% CI, 3.2-31.8% versus 50.0%; 95% CI, 2.3-88.1%; P = 0.14). The addition of TBI at 2-4 Gy to the Flu-Mel-based regimens or the Flu-CY-based regimens did not show a significant impact on relapse/progression (P = 0.89).
Eight patients experienced NRM-viral infection in three patients, organ failure in two patients, chronic GvHD in two patients and idiopathic pneumonia syndrome in one patient. The cumulative incidences of estimated NRM at 100 days and 5 years were 10.9% (95% CI, 3.9-21.8%) and 22.7% (95% CI, 9.3-39.6%), respectively. According to the disease status at transplantation, the 5-year cumulative incidences of NRM were 18.4% (95% CI, 1.9-48.5%) in the patients with CR or PR and 25.6% (95% CI, 8.7-46.7%) in those with progressive/refractory disease (P = 0.53; Figure 3a ). Univariate analysis for NRM identified IgG levels of o700 mg/dL (HR, 9.05; 95% CI, 1.43-57.3; P = 0.02) and maleness (HR, 10.0; 95% CI, 1.30-77.6; P = 0.03) as higher risk factors for NRM ( Table 2 ). The incidences of NRM at 5 years were 9.3% (95% CI, 0.4-35.4%) in patients with IgG of ⩾ 700 mg/dL and 32.0% (95% CI, 12.5-53.5%) in those with IgG of o 700 mg/dL (P = 0.02; Figure 3b ). The incidences of NRM at 5 years were 7.0% (95% CI, 0.4-28.1%) in female patients and 41.2% (95% CI, 15.1-65.9%) in males (P = 0.01; Figure 3c ). In the female patients (n = 26), one patient died of idiopathic pneumonia syndrome and two died of recurrent lymphoma. In contrast, in the male patients (n = 20), seven died of chronic GvHD (n = 2), viral infection (n = 3) or organ failure (n = 2), but none died of recurrent lymphoma. Other variables such as age, disease status and number of chemotherapies before transplantation and stem cell source did not show any impact on NRM (Table 2 ).
GvHD Forty-one patients could be assessed in terms of acute and chronic GvHD; the incidence of grade II-IV acute GvHD was 34.8% (95% CI, 21.4-48.6%). Fifteen of these 41 patients had grade II acute GvHD, one had grade III and no patient developed grade IV acute GvHD. The incidence of chronic GvHD was 41.6% (95% CI, 26.6-56.0%). The median time to onset of chronic GvHD was 4.3 months. Four of the 41 patients had limited chronic GvHD, whereas 14 patients developed extensive chronic GvHD. The stem cell source had no significant impact on the incidence of grade II-IV acute GvHD (P = 0.25) and chronic GvHD (P = 0.74). The presence of grade II-IV acute GvHD and chronic GvHD treated as time-dependent covariates did not influence PFS (HR, 0.55; 95% CI, 0.15-1.99; P = 0.36; and HR, 0.81; 95% CI, 0.19-3.42; P = 0.78, respectively).
DISCUSSION
The definitive management of relapsed/refractory FL remains controversial due to the large number of available treatment options, such as chemotherapy, radioimmunotherapy, auto-SCT and allo-SCT. Although HDT followed by auto-SCT could not be recommended for CR1 patients with FL as consolidation therapy, 8, 20 the randomized European CUP trial showed that HDT has a definitive role in patients with relapsed disease. 21 In the era of rituximab, there have been no randomized studies to compare auto-SCT and standard chemotherapy in relapsed FL. Retrospective analysis of relapsed/refractory FL patients enrolled in the FL2000 study suggested that HDT as consolidation therapy at first relapse/progression for FL is a promising therapeutic strategy. 22 However, increasing evidence of the benefit of rituximab and various other new drugs [23] [24] [25] [26] have brought into question the appropriate place for auto-SCT in the treatment algorithm of FL in recent years because previous studies showed that auto-SCT could not be offered to patients who are beyond PR2 or CR2, or have received three or more previous chemotherapy regimens. 9, 10, 27 In this study, only three patients received HDT followed by auto-SCT before allo-SCT. We speculated that there were three reasons why only a few patients were treated with HDT. First, second-or third-line conventional regimens might have been employed for the patients who desired to receive rituximab-containing regimens or other agents such as Flu or bendamustine rather than HDT or who had a limited stage at relapse. Second, late relapse and the development of secondary malignancies were of concern.
28,29 Third, we have generally preferred allo-SCT to auto-SCT.
Allo-SCT is another curative treatment option for patients with relapsed/refractory FL. As an immunologic GVL effect is suggested by a reduction of relapse/progression, allo-SCT could induce long-term remission for patients who are ineligible for auto-SCT. One prospective and several retrospective comparison studies between auto-SCT and allo-SCT for relapsed FL have been reported. [28] [29] [30] [31] [32] [33] These studies showed that allo-SCT could reduce the incidence of relapse and progression. However, there was no difference in OS between auto-SCT and allo-SCT because patients who underwent allo-SCT had an increased risk of NRM, so a decreased risk of NRM is a matter of utmost concern. The trials from the MD Anderson group and the Cancer and Leukemia Group B reported excellent results of allo-SCT with Flu-CY-based conditioning regimens for patients with chemosensitive relapsed FL from mostly HLA-identical donors. 11, 12 The estimated survival rates were 85% in the MD Anderson study (n = 47) and 81% in the Cancer and Leukemia Group B study (n = 16). These studies revealed that allo-SCT with Flu-CY-based conditioning regimens is a potentially curative strategy for patients with chemosensitive disease. However, the effect of Flu-CY-based regimens has not been obvious for patients with progressive/refractory disease.
The GELTAMO group performed a prospective trial of allo-SCT with the Flu-Mel conditioning regimen for 37 patients with FL. 14 Although seven of these 37 patients (18%) had refractory disease at the time of transplantation, only three patients showed relapse/progressive disease after allo-SCT, and the cumulative incidence of relapse/progression at 4 years was 8%. However, the incidence of NRM at 4 years was high (71%), the 4-year OS rates Abbreviations: BM = bone marrow; CI = confidence interval; HR = hazard ratio; NRM = nonrelapse mortality; OS = overall survival; PB = peripheral blood. were 71% in CR patients, 48% in PR patients and 29% in progressive/refractory disease. It was concluded that the Flu-Mel regimen exhibited a direct antitumor effect, but long-term survival could be obtained by patients with chemosensitive disease. Progressive/refractory FL before transplant was identified as a risk factor for NRM. 14 We analyzed 46 patients with advanced FL who underwent allo-SCT with RIC regimens retrospectively. Most of the patients (96%) received Flu-Mel-based regimens (74%) or Flu-CY-based regimens (22%). The 5-year OS and PFS were 80.7 and 74.9% in the patients with CR or PR and 66.1 and 55.1% in the patients with progressive/refractory disease. Focusing on the conditioning regimens, the 5-year relapse/progression rate for patients with progressive/refractory disease was lower in the Flu-Mel-based regimens (13.8%) than in the Flu-CY-based ones (50.0%), but there was no significant difference (P = 0.14). Residual tumors after conditioning therapies of allo-SCT could be eliminated by the GVL effect, and this effect should appear after donor T-cell immune reconstitution. The conditioning therapies have a role in controlling tumor cells until the appearance of the GVL effect, especially in progressive/refractory disease. Our data and the GELTAMO data 14 indicate that Flu-Mel-based regimens might be readily controllable until the appearance of the GVL effect. In the meantime, the GELTAMO group reported that progressive/ refractory disease was associated with an increased risk of NRM.
14 However, in our study, there was no significant difference in the 5-year NRM between the patients with CR or PR and those with progressive/refractory disease (Figure 3a) . The difference between these results might have been caused by the fact that the GELTAMO study included a large proportion of patients who did not have an ideal performance status (PS).
14 In our study, most of the patients (89%) had a favorable PS (ECOG PS 0-1). PS at the time of transplantation might affect the NRM.
Recent reports of auto-SCT have shown that OS at 5 years is 70% (63-72%). 10, 27, 28 These data and our data demonstrate that both auto-SCT and allo-SCT are effective treatment options for the patients with relapsed/refractory FL. We consider that auto-SCT could be indicated for patients with chemosensitive disease in PR2 or CR2 who have received less than three previous chemotherapy regimens. In contrast, patients who are beyond PR2 or CR2, have received three or more chemotherapy regimens, have relapsed after auto-SCT or have chemoresistant disease should be offered allo-SCT.
In this study, univariate analysis revealed that low IgG levels of o700 mg/dL at the time of transplantation were associated with a higher risk of NRM (HR, 9.05; 95% CI, 1.43-57.3; P = 0.02). Causes of death in those with low IgG levels were infections (66%), organ failure (17%) and chronic GvHD (17%). Although a double-blinded randomized study showed that the use of prophylactic immunoglobulin in allo-SCT had no benefit over a placebo, 34 we should consider immunoglobulin supplementation especially in FL patients with a low IgG level, for example, o700 mg/dL.
The impact of gender on the clinical outcome of patients with FL or diffuse large B-cell lymphoma has been reported. 35 Riihijärvi et al. 35 demonstrated that female patients treated with immunochemotherapy had significantly better PFS than males. However, there were no differences in response and PFS when these patients were treated with first-line chemotherapy without rituximab. It was speculated that gender-associated genetic polymorphism contributed to the response to rituximab. In the present study, there was no difference in the risk of relapse/ progression between men and women and so gender might not influence relapse/progression for patients with FL after allo-SCT. However, multivariate analysis revealed that OS was inferior in male patients compared with that in females (Table 3) . Inferior OS was caused by an increased risk of NRM ( Figure 3c ). As the patients (n = 2) who died of chronic GvHD received transplants from male donors and five of the seven patients passed away within 3.5 months of transplantation, sex-mismatched donors (female to male) did not influence the higher death rate. However, as six of the seven male patients suffered from a low IgG level at the time of transplantation, there was a possibility that this variable might be one of several causes of an increased risk of NRM.
In conclusion, our study may indicate that allo-SCT is a valuable treatment option, even for patients with progressive/refractory FL. However, the retrospective nature of the analysis in our study harbors the risk of selection bias effects. Prospective trials will thus be required to demonstrate the optimal therapy for patients with progressive/refractory FL.
